Keynote: ADC: Drug Development Challenges- What We are Measuring and What Does it Matter?

Tuesday, October 22, 2024

1:30 PM – 2:30 PM MT

Location:150 DEFG

Keynote Speaker(s)

Malaz Abutarif, PhD

Vice President, Head of Quantitative and Clinical Pharmacology
DSI

Moderator(s)

Enaksha Wickremsinhe, PhD (he/him/his)

Bioassay Development Lead
Bill and Melinda Gates Medical Research Institute
Cambridge, Massachusetts

Several examples of the use of exposure-response analyses for efficacy and safety endpoints will be presented. These are important to define and optimize dose and dosing regimen. These analyses are conducted using multiple analytes and the type of assay used can dictate the interpretation of the results.

Learning Objectives:

Understand the use of exposure response analyses for efficacy and safety endpoints in drug development
Importance of dose optimization and the balance of different safety and efficacy
Assay development choices can influence what can and cannot be done for dose optimization